QSAR Studies, Synthesis, and Biological Evaluation of New Pyrimido-Isoquinolin-Quinone Derivatives against Methicillin-Resistant Staphylococcus aureus .
Juan Andrades-LagosJavier Campanini-SalinasGianfranco SabadiniVíctor AndradeJaime Mella-RaipánDavid Vásquez-VelásquezPublished in: Pharmaceuticals (Basel, Switzerland) (2023)
According to the WHO, antimicrobial resistance is among the top 10 threats to global health. Due to increased resistance rates, an increase in the mortality and morbidity of patients has been observed, with projections of more than 10 million deaths associated with infections caused by antibacterial resistant microorganisms. Our research group has developed a new family of pyrimido-isoquinolin-quinones showing antibacterial activities against multidrug-resistant Staphylococcus aureus . We have developed 3D-QSAR CoMFA and CoMSIA studies (r 2 = 0.938; 0.895), from which 13 new derivatives were designed and synthesized. The compounds were tested in antibacterial assays against methicillin-resistant Staphylococcus aureus and other bacterial pathogens. There were 12 synthesized compounds active against Gram-positive pathogens in concentrations ranging from 2 to 32 µg/mL. The antibacterial activity of the derivatives is explained by the steric, electronic, and hydrogen-bond acceptor properties of the compounds.
Keyphrases
- methicillin resistant staphylococcus aureus
- antimicrobial resistance
- staphylococcus aureus
- gram negative
- multidrug resistant
- structure activity relationship
- global health
- silver nanoparticles
- end stage renal disease
- molecular docking
- ejection fraction
- public health
- biofilm formation
- chronic kidney disease
- molecular dynamics
- newly diagnosed
- drug resistant
- peritoneal dialysis
- cardiovascular events
- prognostic factors
- type diabetes
- klebsiella pneumoniae
- cystic fibrosis
- risk factors
- escherichia coli
- essential oil
- coronary artery disease
- cardiovascular disease
- wound healing